Screening Chest CT to Detect Interstitial Lung Disease in Systemic Sclerosis

项目摘要/摘要 候选人：伯恩斯坦博士是哥伦比亚大学风湿病学系的医学助理教授 大学。她是一名临床研究员，共发表了12篇和7篇第一作者原创研究论文，以前 来自关节炎基金会和KL2的资金，以及目前来自风湿病研究的资金 基金会。她拥有临床和翻译调查硕士学位。她的长期职业目标是 成为风湿病学的独立研究员，领导临床和流行病学 系统性硬化症(SSC)早期间质性肺病(ILD)的研究及WHO的发展和检测 SSC中预防ILD的干预措施。职业发展计划：伯恩斯坦博士和她的导师 制定了一份职业发展计划，目的是在K23奖励期结束时实现独立， 包括培训先进的流行病学方法和统计建模、定性和定量肺 成像、临床试验和多中心研究。这些新的技能和知识将使伯恩斯坦博士能够 在SSC从事专注于ILD预防的独立临床和流行病学研究员的职业生涯， 并在K23的第四年提交具有竞争力的R01申请。环境：伯恩斯坦博士 医学部受保护的时间、设施、资源和专家支持以完成 K23中概述的指导研究和职业发展活动。医学部和 风湿病部门保证至少75%的受保护时间用于研究和职业生涯 发展。她经常有机会与其他调查人员进行智力互动，包括 有机会出席与她所在领域相关的大量经常性会议和研讨会并发表演讲 研究的成果。她还将在哥伦比亚大学邮递员公共学院从事相关课程 健康。研究：在大卫·莱德尔博士和琼博士领导的专家指导团队的指导下 伯恩斯坦博士将对220名新转诊的患有自闭症的成年人进行一项双中心前瞻性队列研究 来实现她的目标。这项研究的中心假设是屏幕检测到的SSc中的ILD既是生物学上的 尽管没有症状，但在临床上是相关的，因为它(1)与ILD的生物标志物有关 和(2)出现临床症状和功能受限的先兆，因此可能代表一个“窗口” 干预的“机会”。在目标1中，伯恩斯坦博士将进行一项横断面研究，以确定 筛查发现的系统性红斑狼疮的患病率、临床特征和生物标志物分布。在《目标2》中，她将表演一段 筛查型ILD在SSC中的进展情况的纵向研究。在K23指导下完成这项工作 研究和培训先进的流行病学方法和统计建模、定性和 定量肺成像、临床试验和多中心研究将使她成为一名成功的 独立调查员。

Project Summary/Abstract Candidate: Dr. Bernstein is Assistant Professor of Medicine in the Division of Rheumatology at Columbia University. She is a clinical investigator with 12 total and 7 first-author original research publications, previous funding from the Arthritis Foundation and a KL2, and current funding from the Rheumatology Research Foundation. She has a Master’s Degree in Clinical and Translational Investigation. Her long-term career goal is to become an independent investigator in rheumatology who leads both clinical and epidemiological investigations of early interstitial lung disease (ILD) in systemic sclerosis (SSc), and who develops and tests interventions for the prevention of ILD in SSc. Career Development Plan: Dr. Bernstein and her mentors have crafted a career development plan intended to lead to independence by the end of the K23 award period, including training in advanced epidemiological methods and statistical modeling, qualitative and quantitative lung imaging, and clinical trials and multicenter studies. These new skills and knowledge will allow Dr. Bernstein to pursue a career as an independent clinical and epidemiologic investigator focused on prevention of ILD in SSc, and to submit a competitive R01 application during the fourth year of the K23. Environment: Dr. Bernstein has the protected time, facilities, resources, and expert support of the Department of Medicine to accomplish the mentored research and career development activities outlined in the K23. The Department of Medicine and Division of Rheumatology have guaranteed at least 75% protected time to devote to research and career development. She has regular opportunities for intellectual interactions with other investigators, including the opportunity to attend and present at a large number of recurring conferences and seminars relevant to her area of research. She will also engage in relevant coursework at the Columbia University Mailman School of Public Health. Research: Under the guidance of her expert mentorship team, led by Drs. David Lederer and Joan Bathon, Dr. Bernstein will perform a two-center prospective cohort study of 220 newly referred adults with SSc to achieve her Aims. The central hypothesis of this study is that screen-detected ILD in SSc is both biologically and clinically relevant, despite the absence of symptoms, because it (1) is associated with biomarkers of ILD and (2) precedes the onset of clinical symptoms and functional limitation and may therefore represent a “window of opportunity” for intervention. In Aim 1, Dr. Bernstein will conduct a cross-sectional study to establish the prevalence, clinical features, and biomarker profile of screen-detected ILD in SSc. In Aim 2, she will perform a longitudinal study to examine the progression of screen-detected ILD in SSc. Performing this K23 mentored research and obtaining training in advanced epidemiological methods and statistical modeling, qualitative and quantitative lung imaging, and clinical trials and multicenter studies will position her to become a successful independent investigator.